Search results

Lege Artis Medicinae

DECEMBER 10, 2019

[The adverse effects of smoking on our respiratory system based on data of the Hungarian Public Health Screening 2010-2018 ]


[The regular smoking with or without clinical symptoms causes structural changes in the lung tissue and this is reflected in res­pi­ratory function tests. During the last 9 years of Hungary's comprehesive health promotion screening (MÁESZ) between 2010 and 2018, spiro­metric examinations (PEF, FEV1, MEF25-75, FVC) were performed on 70822 women and 60187 men. We used the percentage of predictive values in the analysis to describe the deviation from normal. The carbon monoxide (eCO) content measurement of the exhaled air (in ppm) was performed on 24899 women and 22340 men. The COPD Evaluation Ques­tionnaire (CAT) was completed by 4166 wo­men and 3170 men. All four parameters of spirometry showed lower values for smokers in both sexes, but in men they were lower than in women. Ageing lowered significantly the values. The rate of changes from normal predictive values and the difference between smokers and non-smokers was the highest for MEF25-75 and FVC. The expiratory CO content (eCO) was significantly higher in smokers than in non-smokers in all age groups. In smokers, the incidence in percent of abnormal CAT score was significantly higher. Respiratory screening tests reveal the harmful effects of smoking, even without clinical symptoms, and indicate the risk of developing COPD.]

Clinical Oncology

DECEMBER 05, 2017



[Radiotherapy with protons is a promising technology in the fi eld of modern radiation oncology. From a physical point of view, radiotherapy with protons has important advantages compared to the currently used photons due to its unique energy absorption profi le, which may result in a better local tumor control and reduced radiation-induced side effects. Increasing number of patients is treated with protons and carbon-ions. Our report aim to present the current status of proton radiotherapy including physical and technological aspects, standard and non-standard indications, ongoing clinical trials and the proton vs. photon debate in terms of patient selection.]

Lege Artis Medicinae

MARCH 20, 2017

[Based on recent evidences, for what kind of diseases are the Hungarian thermal waters beneficial?]


[Hungary has extremely favorable geothermal facilities, resulting in a leadership role in the usage of thermal water for medical purposes and for publishing medical studies. In the recent decades, a total of 40 balneological subject studies were published in English language journals with impact factors, among these 25 original articles dealing with musculoskeletal disorders, as well as inflammatory and metabolic parameters, dermatological and gynecological diseases; besides these, five experimental works and ten reviews, editorial letters, and other issues. In addition, 20 papers have been published in Hungarian medical journals on the topic of musculoskeletal disorders, including six double-blind clinical studies and six single-blind studies. Based on the published domestic and foreign publications, as other studies have not refuted, Hungarian mineral waters, irrespective of mineral content and concentration of the water, have pain killing effect at patients suffering from degenerative musculoskeletal disorders, chronic low back pain and sometimes improve the quality of life of the patients. Based on small number of data the sulfur and salt bath may be beneficial for dermatologic and gynecologic disorders, while carbon dioxide bath, dry carbonic snow, and mofetta may be beneficial in cardiac and vascular rehabilitation; radon bath and radon cave affect the endocrine system; however, to prove it, a study of a large number of patients are required. ]

Lege Artis Medicinae

JULY 20, 2015

[Treatment of chronic Pseudomonas aeruginosa lung infections in cystic fibrosis with inhaled tobramycin]


[BACKGROUND - Intermittent or chronic pulmonary infections caused by Pseudo­monas aeruginosa (Pa) deteriorate clinical status and worsen lung function in patients with cystic fibrosis (CF). The prognosis of the disease and life expectancy of patients are substantially dependent on lung infections and inflammation; therefore the primary goal of the treatment is the early termination of the infection. PATIENTS AND METHODS - Efficacy of tobramycin (TOBI® 300 mg/5 mL solution for inhalation, henceforth TOBI®) inhalation in Pa pulmonary infections was studied in a non-interventional, observational, open-label, single-arm trial in subjects with CF. Fifty-three patients aged six to 31 years (averaged 15.8 years) were enrolled into the study. Three treatment cycles of TOBI® inhalation (28 days on drug, 28 days off drug) plus 6 months observational period were evaluated. Primary endpoint was changing in the predictive values of forced expiratory volume in 1 sec (FEV1) compared to the initial values after three cycles of the treatment. Secondary endpoints were changing in the FEV1 predictive values at the end of the complete study compared to the initial values; ratios of patients with decreased density of originally Pa-positive result of sputum culture; as well as safety and tolerability of the TOBI® treatment. RESULTS - FEV1 and FEV1% results were unchanged comparing to the initial values at the end of the treatment and after the observational period in the whole study population. However, sputum cultures became negative in 47.2% of all subjects as a result of the treatment, and the FEV1 values were gradually increased in these patients: after the third treatment cycle plus 160 mL, and at the end of the study plus 110 mL comparing to the initial values. Similar considerable increase was detected in the predictive FEV1% in this sub-group: after the first cycle plus 5.2%, at the end of third cycle plus 7%, after the observational period above 3.8% considering the starting results. CONCLUSIONS - TOBI® inhalation proved to be effective in improvement of lung function results and eradication of infection in our patients with Pa positive CF. The treatment was well tolerated and safe.]

Lege Artis Medicinae

SEPTEMBER 20, 2005



[INTRODUCTION - Gastroesophageal reflux is known to cause chronic cough and it is also implicated in worsening of asthma. We conducted a prospective study to examine the clinical significance of gastroesophageal reflux disease in asthmatic patients with chronic cough, to analyse the temporal relationship between reflux events and coughing and to assess the effect of esomeprazole treatment on respiratory symptoms and lung function in these patients. PATIENTS AND METHODS - 126 asthmatic patients with chronic dry cough were studied. Diagnosis of gastroesophageal reflux disease was based on typical symptoms and the effectiveness of therapeutic test or on pH monitoring, while control group consisted of the patients without gastroesophageal reflux (negative pH results). The study group patients received the proton pump inhibitor esomeprazole (40 mg/day for three months) and standard treatment for asthma was continued. During the study pulmonary function tests (forced expiratory volume in one second and peak expiratory flow) were evaluated four times and the reflux symptom scores as well, using a questionnaire. RESULTS - The results of pH monitoring showed that 64% of cough episodes were related to acid reflux and in 91% of reflux events preceded coughing. Esomeprazole treatment (40 mg/day for three months) not only diminished gastroesophageal reflux symptoms but also improved asthma outcome measures. Baseline pulmonary function values increased significantly together with a decrease in symptom scores and the use of rescue medication. In most patients included in the extended part of the study for another three months, the dose of inhaled steroids could be reduced with sustained therapy against gastroesophageal reflux. CONCLUSION - Our data shows that reflux events preceded coughing in most cases and that treatment of gastroesophageal reflux disease caused an improvement in different outcome measures of asthma suggest that gastroesophageal reflux disease worsens asthma and its treatment is of clinical importance in the effective management of these patients.]

Lege Artis Medicinae

DECEMBER 20, 2004


MOHÁCSI Attila, LIZANECZ Erzsébet, ÉDES István, CZURIGA István

[The pathobiological aim of treatment with angiotensin converting enzyme inhibitor is to restore the balance between nitrogen-monoxide and angiotensin II due to inhibition of blood and tissue angiotensin converting enzyme. The clinical consquences of the inhibition of tissue angiotensin converting enzyme in patients with additionally high (HOPE) and low (EUROPA) cardiovascular risk without left ventricular dysfunction has already been demonstrated. Ramipril and the perindopril reduce the risk of combined end-point of these trials such as cardiovascular mortality, reinfarction and resuscitated sudden cardiac death. However, pharmacological and genetic differences in blocking of tissue angiotensin converting enzyme may influence the cardioprotective effect of various angiotensin converting enzyme inhibitors. Thus new, well-designed, controlled clinical trials are needed to determine the role of angiotensin converting enzyme inhibitor with different tissue angiotensin converting enzyme affinity in cardiovascular disease.]

Hungarian Radiology

SEPTEMBER 20, 2008

[The bubble-sign of spontaneous pneumoperitoneum]


[INTRODUCTION - Pneumoperitoneum is a reliable indicator of serious underlying damage. There are four etiologic categories of extraluminal-intraperitoneal gas collections: spontaneous, iatrogenic, traumatic and criminal perforations. The erect posteroanterior chest radiograph is the most sensitive plain film projection for detecting pneumoperitoneum and it may show 0.5-1 ml free abdominal gas when meticulous radiographic techniques (lateral, oblique, air-gap, lordotic, inspiratory and expiratory exposures) are used. The appearances of extraluminal gas collections are specified by physical rules and individual preferences. The bubble-sign is an uncommon, pathognomonic phenomenon. CASE REPORT - A case of an 86 years old female patient with spontaneous pneumoperitoneum, diagnosed on the basis of the bubble-sign is presented. On erect, lordotic inspiratory chest film, right medial inversion of diaphragm, left pleural effusion, emphysema, cardiomegaly and aortectasia were observed. The bubble-sign and hydromediastinum became evident in the right phrenicocostal angle on expiratory view. Our patient expired before the surgical intervention.The postmortem demonstrated double peptic duodenal ulcers; the older ulcer had penetrated and encapsulated in the hepatoduodenal ligament, while the more recent one perforated through the intraperitoneal space. CONCLUSION - Routine upright chest films are valuable screening tools for uncommon signs of pneumoperitoneum, also.]

Lege Artis Medicinae

DECEMBER 20, 2003


VIZI Éva, CSOMA Zsuzsanna, HUSZÁR Éva

[Exercise-induced bronchoconstriction describes the transient narrowing of the airways occurring during and most often after vigorous exercise. The mechanism of exercise-induced bronchoconstriction remains elusive, although airway drying and cooling plays a prominent role. The severity of this reaction depends on the temperature and the water content of the inspired air, the type and concentration of air pollutants inspired and the intensity of the exercise. Diagnosis of exercise-induced bronchoconstriction should include baseline spirometry followed by an exercise challenge test. The exercise can be a free-running test or a laboratory based test using a cycle-ergometer or a treadmill. Pre- and post-exercise pulmonary function should be compared, 10%-15% postexercise fall in forced expiratory volume in 1 second (FEV1) is used as a diagnostic criteria (10% in laboratory test, 15% in free-running test). Heat loss, water loss, post exertional airway rewarming and the role of several mediators have been proposed as possible mechanisms responsible for the airway obstruction induced by exercise. Exercise-induced bronchoconstriction can be easily diagnosed and treated in the majority of patients. When properly treated, asthmatic individuals should be able to participate or compete in the majority of sports.]

Lege Artis Medicinae

APRIL 21, 2006



[Insulin detemir is a neutral, soluble, long-acting insulin analogue in which the amino acid threonineB30 has been removed and the LysB29 acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to dihexamerisate and reversibly bind to human albumin upon administration. This brand new principle (self association and albumin binding) ensures slow absorption and a prolonged and consistent metabolic effect without a marked peak for up to 24 hours in patients both with type 1 and type 2 diabetes mellitus. Results of large clinical trials have shown that detemir can be efficiently used as basal insulin, supplemented with human regular insulin or aspart insulin taken before the main meals, in both type 1 and type 2 diabetes. Available data clearly demonstrate that the use of this insulin is associated with decreased variability of the fasting blood glucose values. In some of the studies the risk of (mostly nocturnal) hypoglycaemic episodes also dropped. It is important to note that patients using insulin detemir gained less or no weight compared to the group of patients treated with neutral protamine Hagedorn (NPH) insulin. Evaluation of long-term and wide-spread application of detemir needs further observations. Such trials are being conducted worldwide.]